References

therapeutic

Южно-Российский журнал терапевтической практики

South Russian Journal of Therapeutic Practice

2712-81563033-8344

РостГМУ

10.21886/2712-8156-2021-2-1-17-24

therapeutic-119

Research Article

ОБЗОРЫ

REVIEWS

COVID-19 и ожирение: что известно об особенностях патогенеза и лечения?

COVID-19 and obesity: what is known about the features of pathogenesis and treatment?

Канорский

С. Г.

Kanorskii

S. G.

Канорский Сергей Григорьевич — доктор медицинских наук, профессор, заведующий кафедрой терапии № 2 ФПК и ППС.

Краснодар

Sergej G. Kanorskii — MD, Professor, head of chair of therapy № 2 Faculty of Advanced Training and Professional.

Krasnodar

kanorskysg@mail.ru

ФГБОУ ВО Кубанский государственный медицинский университет Минздрава РоссииРоссияKuban State Medical UniversityRussian Federation

2021

23032021

211723

2021

Канорский С.Г.

Kanorskii S.G.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.therapeutic-j.ru/jour/article/view/119

Увеличение распространенности избыточного веса и ожирения является проблемой общественного здравоохранения во всем мире. Во время пандемии COVID-19 ожирение связано с более высоким риском тяжелого течения и неблагоприятного клинического исхода инфекции SARS-CoV-2. Это может быть обусловлено с хроническим системным воспалением, нарушением иммунного ответа и метаболическими нарушениями у пациентов с ожирением. С целью установления возможных патогенетических связей между ожирением и COVID-19 проведён анализ экспериментальных и клинических исследований, их метаанализов, обзоров литературы из базы данных PubMed / MedLine по ключевым словам «COVID-19» и «obesity». В настоящем обзоре обсуждены потенциальные особенности патогенеза и лечения пациентов с ожирением и COVID-19.

The increasing prevalence of overweight and obesity is a public health problem worldwide. During the COVID-19 pandemic, obesity is associated with a higher risk of severe disease and adverse clinical outcome of SARS-CoV-2 infection. It may be associated with chronic systemic inflammation, impaired immune response and metabolic disturbances in obese patients. In order to establish possible pathogenetic links between obesity and COVID-19, an analysis of experimental, clinical studies, their meta-analyzes, literature reviews from the PubMed/MedLine database was carried out using the keywords «COVID-19» and «obesity». This review discusses the potential pathogenesis and treatment features of obese patients with COVID-19.

COVID-19ожирениеSARS-CoV-2

COVID-19obesitySARS-CoV-2

References1

Bluher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288-298. doi: 10.1038/s41574-019-0176-8.

NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body- mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128-9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627-2642. doi: 10.1016/S0140-6736(17)32129-3.

Zupo R, Castellana F, Sardone R, Sila A, Giagulli VA, Triggiani V, et al. Preliminary trajectories in dietary behaviors during the COVID-19 pandemic: a public health call to action to face obesity. Int J Environ Res Public Health. 2020;17(19):7073. doi: 10.3390/ijerph17197073.

Barrea L, Pugliese G, Framondi L, Di Matteo R, Laudisio D, Savastano S, et al. Does Sars-Cov-2 threaten our dreams? Effect of quarantine on sleep quality and body mass index. J Transl Med. 2020;18(1):318. doi: 10.1186/s12967-020-02465-y.

Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490-502. doi: 10.1016/j.tim.2016.03.003/.

Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill. 2020;25(5):200062. doi: 10.2807/1560-7917.ES.2020.25.5.2000062.

Liang M, Gao L, Cheng C, Zhou Q, Uy JP, Heiner K, et al. Efficacy of face mask in preventing respiratory virus transmission: a systematic review and meta-analysis. Travel Med Infect Dis. 2020;36:101751. doi: 10.1101/2020.04.03.20051649.

Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schunemann HJ; COVID-19 Systematic Urgent Review Group Effort (SURGE) study authors. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395(10242):1973-1987. doi: 10.1016/S0140-6736(20)31142-9.

Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, Villamizar-Pena R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623. doi: 10.1016/j.tmaid.2020.101623.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: key points for the radiologist. N Engl J Med. 2020;382(8):727-733. doi: 10.1056/NEJMoa2001017.

Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606. doi: 10.1136/bmj.m606.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with CO-VID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3.

Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-2059. doi: 10.1001/jama.2020.6775.

RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704. doi: 10.1056/NEJMoa2021436.

Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020. Mar 31:e3319. doi: 10.1002/dmrr.3319. Online ahead of print.

Piva S, Filippini M, Turla F, Cattaneo S, Margola A, De Fulviis S, et al. Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. J Crit Care. 2020;58:29-33. doi: 10.1016/j.jcrc.2020.04.004.

Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458-464. doi: 10.15585/mmwr.mm6915e3.

de Siqueira JVV, Almeida LG, Zica BO, Brum IB, Barcelo A, de Siqueira Galil AG. Impact of obesity on hospitalizations and mortality, due to COVID-19: a systematic review. Obes Res Clin Pract. 2020;14(5):398-403. doi: 10.1016/j.orcp.2020.07.005.

Tamara A, Tahapary DL. Obesity as a predictor for a poor prognosis of COVID-19: a systematic review. Diabetes Metab Syndr Clin Res Rev. 2020;14(4):655-659. doi: 10.1016/j.dsx.2020.05.020.

Hussain A, Mahawar K, Xia Z, Yang W, El-Hasani S. Obesity and mortality of COVID-19. Meta-analysis. Obes Res Clin Pract. 2020;14(4):295-300. doi: 10.1016/j.orcp.2020.07.002.

Barrasa H, Rello J, Tejada S, Martin A, Balziskueta G, Vinuesa C, et al. SARS-CoV-2 in Spanish intensive care: early experience with 15-day survival in Vitoria. Anaesth Crit Care Pain Med. 2020;39(5):553-561. doi: 10.1016/j.accpm.2020.04.001.

Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020;28(7):1195-1199. doi: 10.1002/oby.22831.

Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q, et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care. 2020;43(7):1392-1398. doi: 10.2337/dc20-0576.

Hajifathalian K, Kumar S, Newberry C, Shah S, Fortune B, Kris-ko T, et al. Obesity is associated with worse outcomes in CO-VID-19: analysis of early data from New York City. Obesity (Silver Spring). 2020;28(9):1606-1612. doi: 10.1002/oby.22923.

Zheng KI, Gao F, Wang X-B, Sun QF, Pan KH, Wang TY, et al. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020;108:154244. doi: 10.1016/j.metabol.2020.154244.

Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Association of obesity and its genetic predisposition with the risk of severe COVID-19: analysis of population-based cohort data. Metabolism. 2020;112:154345. doi: 10.1016/j.metabol.2020.154345.

Fresan U, Guevara M, Elia F, Albeniz E, Burgui C, Castilla J. Independent role of morbid obesity as a risk factor for COVID-19 hospitalization: a Spanish population-based cohort study. Obesity. 2021;29(1):29-37. doi: 10.1002/oby.23029.

Huang Y, Lu Y, Huang YM, Wang M, Ling W, Sui Y, et al. Obesity in patients with COVID-19: a systematic review and metaanalysis. Metabolism. 2020;113:154378. doi: 10.1016/j.metabol.2020.154378.

Divella R, De Luca R, Abbate I, Naglieri E, Daniele A. Obesity and cancer: the role of adipose tissue and adipo-cytokines-in-duced chronic inflammation. J Cancer. 2016;7(15):2346-2359. doi: 10.7150/jca.16884.

Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-a and IL-6. Diabetes Res Clin Pract. 2005;69(1):29-35. doi: 10.1016/j.diabres.2004.11.007.

Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175-184. doi: 10.1172/JCI29881.

Zatterale F, Longo M, Naderi J, Raciti GA, Desiderio A, Miele C, et al. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front Physiol. 2020;10:1607. doi: 10.3389/fphys.2019.01607.

Muscogiuri G, Pugliese G, Barrea L, Savastano S, Colao A. Obesity: the "Achilles heel" for COVID-19? Metabolism. 2020;108:8-10. doi: 10.1016/j.metabol.2020.154251.

Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451-1454. doi: 10.1038/s41418-020-0530-3.

Payen D, Cravat M, Maadadi H, Didelot C, Prosic L, Dupuis C, et al. A Longitudinal Study of Immune Cells in Severe COVID-19 Patients. Front Immunol. 2020;11:580250. doi: 10.3389/fim-mu.2020.580250.

Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of peripheral lymphocyte subset alteration in CO-VID-19 pneumonia. J Infect Dis. 2020;221(11):1762-1769. doi: 10.1093/infdis/jiaa150.

Green WD, Beck MA. Obesity altered T cell metabolism and the response to infection. Curr Opin Immunol. 2017;46:1-7. doi: 10.1016/j.coi.2017.03.008.

Mclaughlin T, Ackerman SE, Shen L, Engleman E. Role of innate and adaptive immunity in obesity-associated metabolic disease. J Clin Invest. 2017;127(1):5-13. doi: 10.1172/JCI88876.

Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsu-gi M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009;15(8):914-920. doi: 10.1038/nm.1964.

Tse GM, To KF, Chan PK, Lo AW, Ng KC, Wu A, et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol. 2004;57(3):260-265. doi: 10.1136/jcp.2003.013276.

Kruglikov IL, Scherer PE. The role of adipocytes and adipocyte-like cells in the severity of COVID-19 infections. Obesity. 2020;28(7):1187-1190. doi: 10.1002/oby.22856.

Rehan VK, Torday JS. The lung alveolar lipofibroblast: an evolutionary strategy against neonatal hyperoxic lung injury. Antioxidants Redox Signal. 2014;21(13):1893-1904. doi: 10.1089/ars.2013.5793.

El Agha E, Moiseenko A, Kheirollahi V, De Langhe S, Crnkovic S, Kwapiszewska G, et al. Two-way conversion between lipogenic and myogenic fibroblastic phenotypes marks the progression and resolution of lung fibrosis. Cell Stem Cell. 2017;20(2):261-273.e3. doi: 10.1016/j.stem.2016.10.004.

Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193-199. doi: 10.1007/s00592-009-0109-4.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemio-logical and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7.

Butler SO, Btaiche IF, Alaniz C. Relationship between hyperglycemia and infection in critically ill patients. Pharmacotherapy. 2005;25(7):963-976. doi: 10.1592/phco.2005.25.7.963.

Mirabelli M, Chiefari E, Puccio L, Foti DP, Brunetti A. Potential benefits and harms of novel antidiabetic drugs during COV-ID-19 crisis. Int J Environ Res Public Health. 2020;17(10):3664. doi: 10.3390/ijerph17103664.

Qu H, Zheng Y, Wang Y, Li H, Liu X, Xiong X, et al. The potential effects of clinical antidiabetic agents on SARS-CoV-2. J Diabetes. 2021;13(3):243-252. doi: 10.1111/1753-0407.13135. Chen X, Guo H, Qiu L, Zhang C, Deng Q, Leng Q. Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury. Front Immunol. 2020;11:2056. doi: 10.3389/fimmu.2020.02056.

Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era? J Diabetes Complications. 2020;34(12):107-723. doi: 10.1016/j.jdiacomp.2020.107723.

Heaton NS, Randall G. Multifaceted roles for lipids in viral infection. Trends Microbiol. 2011;19(7):368-375. doi: 10.1016/j.tim.2011.03.007.

Lu Y, Liu DX, Tam JP. Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. Biochem Biophys Res Commun. 2008;369(2):344-349. doi: 10.1016/j.bbrc.2008.02.023.

Lu JC, Chiang YT, Lin YC, Chang YT, Lu CY, Chen TY, et al. Disruption of lipid raft function increases expression and secretion of monocyte chemoattractant protein-1 in 3T3-L1 adipocytes. PLoS One. 2016;11(12): e0169005. doi: 10.1371/journal.pone.0169005.

Li GM, Li YG, Yamate M, Li SM, Ikuta K. Lipid rafts play an important role in the early stage of severe acute respiratory syn-drome-coronavirus life cycle. Microbes Infect. 2007;9(1):96-102. doi: 10.1016/j.micinf.2006.10.015.

Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. doi: 10.1186/1743-422X-2-69.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271. doi: 10.1038/s41422-020-0282-0.

Smit C, Peeters MYM, van den Anker JN, Knibbe CAJ. Chloroquine for SARS-CoV-2: implications of its unique pharmacokinetic and safety properties. Clin Pharmacokinet. 2020;59(6):659-669. doi: 10.1007/s40262-020-00891-1.

Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517-525. doi: 10.1056/NEJMoa2016638.

Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020;383(21):2041-2052. doi: 10.1056/NEJMoa2019014.

Wessels I, Maywald M, Rink L. Zinc as a gatekeeper of immune function. Nutrients. 2017;9(12):1286. doi: 10.3390/nu9121286.

Gammoh NZ, Rink L. Zinc in infection and inflammation. Nutrients. 2017;9(6):624. doi: 10.3390/nu9060624.

De Luis DA, Pacheco D, Izaola O, Terroba MC, Cuellar L, Cabe-zas G. Micronutrient status in morbidly obese women before bariatric surgery. Surg Obes Relat Dis. 2013;9(2):323-327. doi: 10.1016/j.soard.2011.09.015.

Suliburska J, Cofta S, Gajewska E, Kalmus G, Sobieska M, Samborski W, et al. The evaluation of selected serum mineral concentrations and their association with insulin resistance in obese adolescents. Eur Rev Med Pharmacol Sci. 2013;17(17):2396-2400. PMID: 24065235.

Islam MR, Attia J, Ali L, McEvoy M, Selim S, Sibbritt D, et al. Zinc supplementation for improving glucose handling in prediabetes: a double blind randomized placebo controlled pilot study. Diabetes Res Clin Pract. 2016;115:39-46. doi: 10.1016/j.diabres.2016.03.010.

Te Velthuis AJW, van den Worml SHE, Sims AC, Baric RS, Sni-jder EJ, van Hemert MJ. Zn2+ inhibits coronavirus and arterivi-rus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. 2010;6 (11):e1001176. doi: 10.1371/journal.ppat.1001176.

Xue J, Moyer A, Peng B, Wu J, Hannafon BN, Ding WQ. Chloroquine is a zinc ionophore. PLoS One. 2014;9(10):e109180. doi: 10.1371/journal.pone.0109180.

Lin MH, Moses DC, Hsieh CH, Cheng SC, Chen YH, Sun CY, et al. Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. Antiviral Res. 2018;150:155-163. doi: 10.1016/j.antiviral.2017.12.015.

Sierra H, Cordova M, Chen CSJ, Rajadhyaksha M. One hormone two actions: anti- and pro-inflammatory effects of glucocorticoids diana. J Invest Dermatol. 2015;135(2):612-615. doi: 10.1038/jid.2014.371.

Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020;81(1):e13-e20. doi: 10.1016/j.jinf.2020.03.062.

Falzarano D, De Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, et al. Treatment with interferon-a2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19(10):1313-1317. doi: 10.1038/nm.3362.

Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695-1704. doi: 10.1016/S0140-6736(20)31042-4.

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-1578. doi: .1016/S0140-6736(20)31022-9.

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383 (19):1813-1826. doi: 10.1056/nejmoa2007764.

Sheridan PA, Paich HA, Handy J, Karlsson EA, Hudgens MG, Sammon AB, et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes (Lond). 2012;36(8):1072-1077. doi: 10.1038/ijo.2011.208.

Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. Sci Immunol. 2020;5(49):eabd6160. doi: 10.1126/sciimmunol.abd6160.

The authors declare that there are no conflicts of interest present.